New Risk • 21h
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 6.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings are forecast to decline by an average of 6.9% per year for the foreseeable future. Revenue is less than US$1m (CHF275k revenue, or US$340k). New Risk • May 05
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: CHF275k (US$352k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$1m (CHF275k revenue, or US$352k). New Risk • Apr 19
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 68% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings are forecast to decline by an average of 68% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (CHF839k revenue, or US$1.1m). New Risk • Apr 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (CHF839k revenue, or US$1.1m). Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CHF20.60, the stock trades at a trailing P/E ratio of 3.9x. Average trailing P/E is 27x in the Life Sciences industry in Switzerland. Total loss to shareholders of 29% over the past three years. Duyuru • Dec 10
Grupo Landsteiner, S.A. de C.V. y Subsidiarias signed a binding framework agreement to acquire 12 advanced biotech, medtech and digital health projects from Xlife Sciences AG (SWX:XLS) for $450 million. Grupo Landsteiner, S.A. de C.V. y Subsidiarias signed a binding framework agreement to acquire 12 advanced biotech, medtech and digital health projects from Xlife Sciences AG (SWX:XLS) for $450 million on December 8, 2025. A cash consideration of $450 million will be paid by Grupo Landsteiner, S.A. de C.V. y Subsidiarias. Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CHF20.80, the stock trades at a trailing P/E ratio of 3.9x. Average trailing P/E is 28x in the Life Sciences industry in Switzerland. Total loss to shareholders of 31% over the past three years. Duyuru • Oct 17
Xlife Sciences AG to Report First Half, 2026 Results on Sep 24, 2026 Xlife Sciences AG announced that they will report first half, 2026 results on Sep 24, 2026 New Risk • Sep 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swiss stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.5% average weekly change). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (CHF839k revenue, or US$1.1m). Reported Earnings • Sep 26
First half 2025 earnings released: CHF0.53 loss per share (vs CHF0.082 profit in 1H 2024) First half 2025 results: CHF0.53 loss per share (down from CHF0.082 profit in 1H 2024). Net loss: CHF3.05m (down CHF3.52m from profit in 1H 2024). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Duyuru • Sep 24
Xlife Sciences AG to Report Fiscal Year 2025 Results on Apr 28, 2026 Xlife Sciences AG announced that they will report fiscal year 2025 results on Apr 28, 2026 Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CHF22.70, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 33x in the Life Sciences industry in Switzerland. Total loss to shareholders of 12% over the past three years. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. President of the Board of Directors David Deck was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jun 04
Xlife Sciences AG, Annual General Meeting, Jun 24, 2025 Xlife Sciences AG, Annual General Meeting, Jun 24, 2025, at 14:00 W. Europe Standard Time. Location: zurich Switzerland New Risk • May 12
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: CHF835k (US$986k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (CHF835k revenue, or US$986k). Minor Risk Large one-off items impacting financial results. Reported Earnings • Apr 27
Full year 2024 earnings released: EPS: CHF6.00 (vs CHF2.73 in FY 2023) Full year 2024 results: EPS: CHF6.00 (up from CHF2.73 in FY 2023). Net income: CHF34.3m (up 130% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CHF25.40, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 29x in the Life Sciences industry in Switzerland. Total loss to shareholders of 40% over the past three years. Valuation Update With 7 Day Price Move • Apr 10
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CHF19.00, the stock trades at a trailing P/E ratio of 5.1x. Average trailing P/E is 27x in the Life Sciences industry in Switzerland. Total loss to shareholders of 55% over the past three years. New Risk • Apr 06
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (CHF990k revenue, or US$1.1m). Buy Or Sell Opportunity • Mar 31
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 12% to CHF22.40. The fair value is estimated to be CHF29.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 38%. Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CHF23.10, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 33x in the Life Sciences industry in Switzerland. Total loss to shareholders of 43% over the past three years. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CHF20.80, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 30x in the Life Sciences industry in Switzerland. Total loss to shareholders of 49% over the past three years. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CHF18.40, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 36x in the Life Sciences industry in Switzerland. Total loss to shareholders of 60% over the past three years. Buy Or Sell Opportunity • Jan 03
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 8.4% to CHF25.00. The fair value is estimated to be CHF31.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 38%. Buy Or Sell Opportunity • Dec 18
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 26% to CHF24.00. The fair value is estimated to be CHF31.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 38%. Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CHF28.60, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 44x in the Life Sciences industry in Switzerland. Total loss to shareholders of 24% over the past year. Buy Or Sell Opportunity • Oct 30
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 33% to CHF24.80. The fair value is estimated to be CHF31.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 38%. Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CHF27.30, the stock trades at a trailing P/E ratio of 7.4x. Average trailing P/E is 43x in the Life Sciences industry in Switzerland. Total loss to shareholders of 28% over the past year. Valuation Update With 7 Day Price Move • Sep 18
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CHF30.30, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 45x in the Life Sciences industry in Switzerland. Total loss to shareholders of 25% over the past year. New Risk • Sep 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Revenue is less than US$5m (CHF988k revenue, or US$1.2m). Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CHF28.30, the stock trades at a trailing P/E ratio of 10.9x. Average trailing P/E is 46x in the Life Sciences industry in Switzerland. Total loss to shareholders of 29% over the past year. Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to CHF36.00, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 45x in the Life Sciences industry in Switzerland. Total loss to shareholders of 11% over the past year. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CHF38.10, the stock trades at a trailing P/E ratio of 13.5x. Average forward P/E is 38x in the Life Sciences industry in Switzerland. Total returns to shareholders of 17% over the past year. New Risk • Apr 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.6% average weekly change). Earnings are forecast to decline by an average of 143% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1,607% net profit margin). Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Revenue is less than US$5m (CHF1.0m revenue, or US$1.1m). Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CHF47.20, the stock trades at a trailing P/E ratio of 16.7x. Average forward P/E is 38x in the Life Sciences industry in Switzerland. Total returns to shareholders of 51% over the past year. Board Change • Feb 28
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Desiree Dosch was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to CHF49.00, the stock trades at a trailing P/E ratio of 17x. Average forward P/E is 29x in the Life Sciences industry in Switzerland. Total returns to shareholders of 69% over the past year. Duyuru • Oct 20
Xlife Sciences AG (SWX:XLS) acquired 20% stake in 4D Lifetec AG for CHF 23.3 million. Xlife Sciences AG (SWX:XLS) acquired 20% stake in 4D Lifetec AG for CHF 23.3 million on October 18, 2023.Xlife Sciences AG (SWX:XLS) completed the acquisition of 20% stake in 4D Lifetec AG on October 18, 2023. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CHF34.20, the stock trades at a trailing P/E ratio of 11.9x. Average forward P/E is 28x in the Life Sciences industry in Switzerland. Total returns to shareholders of 5.2% over the past year. New Risk • Jun 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6.8% average weekly change). Earnings are forecast to decline by an average of 123% per year for the foreseeable future. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1,392% net profit margin). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (CHF1.0m revenue, or US$1.1m). Duyuru • May 26
Xlife Sciences AG Announces Bernhard Scholz Will Not Stand for Re-Election Xlife Sciences AG announced Except for the incumbent Chairman, Dr. Bernhard Scholz, who, as planned, will not stand for re-election for the next term of office. Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CHF36.40, the stock trades at a trailing P/E ratio of 13.6x. Average forward P/E is 39x in the Life Sciences industry in Switzerland. Total loss to shareholders of 5.9% over the past year. Reported Earnings • Apr 26
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: CHF2.72 (down from CHF11.30 in FY 2021). Net income: CHF14.3m (down 73% from FY 2021). Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 13% p.a. on average during the next 2 years, while revenues in the Life Sciences industry in Switzerland are expected to grow by 11%. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 16% share price gain to CHF34.50, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 38x in the Life Sciences industry in Switzerland. Valuation Update With 7 Day Price Move • Aug 31
Investor sentiment improved over the past week After last week's 16% share price gain to CHF35.90, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 43x in the Life Sciences industry in Switzerland. Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment improved over the past week After last week's 33% share price gain to CHF33.00, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 36x in the Life Sciences industry in Switzerland. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Apr 18
Investor sentiment improved over the past week After last week's 19% share price gain to CHF42.50, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 57x in the Life Sciences industry in Switzerland. Board Change • Feb 11
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Duyuru • Feb 11
Xlife Sciences AG, Annual General Meeting, Jun 20, 2022 Xlife Sciences AG, Annual General Meeting, Jun 20, 2022.